Literature DB >> 34306478

Application of ultrasound combined with enhanced MRI by Gd-BOPTA in diagnosing hepatocellular carcinoma.

Shuwen Ji1, Ziyong Wang2, Shiyong Xia2.   

Abstract

OBJECTIVE: This study aimed to probe into the diagnostic level and clinical value of ultrasound combined with enhanced MRI by Gd-BOPTA in hepatocellular carcinoma (HCC).
METHODS: A total of 58 suspected HCC patients in our hospital from January 2016 to November 2020 were collected as the research subjects, including 37 HCC and 21 non-HCC patients. The diagnostic results of ultrasound and enhanced MRI by Gd-BOPTA were compared, and the microvascular invasion in patients was assessed. The independent risk factors of microvascular invasion were analyzed by logistics regression, and the diagnostic value of these factors was tested by ROC.
RESULTS: The specificity, sensitivity and accuracy of enhanced MRI by Gd-BOPTA were 89.19%, 90.48% and 94.59%, respectively. The specificity, sensitivity and accuracy of ultrasound were 85.71%, 72.97% and 91.89%, and those of combined diagnosis were 76.19%, 97.30%, and 89.66%, respectively. The confirmation rate of microvascular invasion of enhanced MRI by Gd-BOPTA was dramatically higher than with ultrasound. Tumor diameter, comorbid cirrhosis and differentiation degree were independent risk factors of microvascular invasion, and ROC curve revealed that the area under the curve (AUC) of these risk factors was > 0.6.
CONCLUSION: Enhanced MRI by Gd-BOPTA combined with ultrasound has good diagnostic value in HCC patients, and it can be widely used in early HCC diagnosis and clinical examination. AJTR
Copyright © 2021.

Entities:  

Keywords:  HCC; Ultrasound; enhanced MRI by Gd-BOPTA

Year:  2021        PMID: 34306478      PMCID: PMC8290690     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  26 in total

1.  Correlations of ultrasonic features with severity of liver cancer and p16 expression in patients with liver cancer.

Authors:  H Jia; D Yan; Q Xiao; G Zhang
Journal:  Neoplasma       Date:  2018-08-09       Impact factor: 2.575

2.  Detection of small (≤2 cm) HCC in cirrhotic patients: added value of diffusion MR-imaging.

Authors:  Michele Di Martino; Rossella Di Miscio; Gianmaria De Filippis; Concetta Valentina Lombardo; Luca Saba; Daniel Geiger; Carlo Catalano
Journal:  Abdom Imaging       Date:  2013-12

3.  Lipocalin-2: A novel diagnostic marker for hepatocellular carcinoma.

Authors:  Ihab Barsoum; Marwan N Elgohary; Mohamed A A Bassiony
Journal:  Cancer Biomark       Date:  2020       Impact factor: 4.388

4.  Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.

Authors:  Matteo Bonatti; Riccardo Valletta; Giulia A Zamboni; Fabio Lombardo; Maria Senoner; Mariachiara Simioni; Guenther Schifferle; Giampietro Bonatti
Journal:  Eur Radiol       Date:  2019-01-14       Impact factor: 5.315

5.  Long-term outcomes after hepatectomy of huge hepatocellular carcinoma: A single-center experience in China.

Authors:  Qiang Fang; Qing-Song Xie; Jiang-Ming Chen; Shen-Liang Shan; Kun Xie; Xiao-Ping Geng; Fu-Bao Liu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2019-09-11

6.  Hepatocellular carcinoma in patients with no identifiable risk factors.

Authors:  Caitlin A McIntyre; Joanne F Chou; Mithat Gonen; Jinru Shia; Maya Gambarin-Gelwan; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Jeffrey A Drebin; William R Jarnagin; Michael I D'Angelica
Journal:  HPB (Oxford)       Date:  2020-06-24       Impact factor: 3.647

7.  18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.

Authors:  Julian Kirchner; Lino M Sawicki; Cornelius Deuschl; Johannes Grüneisen; Karsten Beiderwellen; Thomas C Lauenstein; Ken Herrmann; Michael Forsting; Philipp Heusch; Lale Umutlu
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

8.  Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis.

Authors:  Li-Na Ma; Xiao-Yan Liu; Zhen-Hui Lu; Li-Gang Wu; Yuan-Yuan Tang; Xia Luo; Yan-Chao Hu; Ting-Ting Yan; Qi Wang; Xiang-Chun Ding; Yan Xie
Journal:  Oncol Lett       Date:  2017-03-22       Impact factor: 2.967

9.  Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Vogel; A Cervantes; I Chau; B Daniele; J M Llovet; T Meyer; J-C Nault; U Neumann; J Ricke; B Sangro; P Schirmacher; C Verslype; C J Zech; D Arnold; E Martinelli
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

View more
  1 in total

Review 1.  Rare earth smart nanomaterials for bone tissue engineering and implantology: Advances, challenges, and prospects.

Authors:  Duraipandy Natarajan; Zhitong Ye; Liping Wang; Linhu Ge; Janak Lal Pathak
Journal:  Bioeng Transl Med       Date:  2021-12-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.